4 ms·
>The present disclosure relates to noninvasive methods, devices, and systems for measuring various blood constituents or analytes, such as glucose. In an embodi
by kken 3y ago
>The present disclosure relates to noninvasive methods, devices, and systems for measuring various blood constituents or analytes, such as glucose. In an embodiment, a light source comprises LEDs and super-luminescent LEDs. The light source emits light at least wavelengths of about 1610 nm, about 1640 nm, and about 1665 nm.
Since when is the Apple watch measureing glucose? It appears they are not fighting about something the was in the original scope of the patent but something that was added/emphasized later.
Difficult to pick sides here.
Massimo was/is the incumbent in their medical space and they are now, to some extend, being disrupted by a consumer-market focused company. Of course they need to defend their territory. On the other hand, this is also not the first instance where Apple is accused of predatory behavior towards potential suppliers.
- ImPostingOnHN 3y ago> Since when is the Apple watch measureing glucose? the patent says, "various blood constituents or analytes" oxygen is a constituent, oxygenation is an analyte, just as an example the word you're quoting, "glucose" appears after the term "such as", which means "possibly including, and not limited to", so this isn't the gotcha you may think it is